These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 15713485)

  • 1. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
    Shia S; Stamos J; Kirchhofer D; Fan B; Wu J; Corpuz RT; Santell L; Lazarus RA; Eigenbrot C
    J Mol Biol; 2005 Mar; 346(5):1335-49. PubMed ID: 15713485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocyte growth factor activator (HGFA): molecular structure and interactions with HGFA inhibitor-1 (HAI-1).
    Eigenbrot C; Ganesan R; Kirchhofer D
    FEBS J; 2010 May; 277(10):2215-22. PubMed ID: 20402765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1.
    Kirchhofer D; Peek M; Li W; Stamos J; Eigenbrot C; Kadkhodayan S; Elliott JM; Corpuz RT; Lazarus RA; Moran P
    J Biol Chem; 2003 Sep; 278(38):36341-9. PubMed ID: 12815039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mouse hepatocyte growth factor (HGF) activator inhibitor type 2 lacking the first Kunitz domain potently inhibits the HGF activator.
    Kataoka H; Itoh H; Nuki Y; Hamasuna R; Naganuma S; Kitamura N; Shimomura T
    Biochem Biophys Res Commun; 2002 Jan; 290(3):1096-100. PubMed ID: 11798188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
    Kirchhofer D; Peek M; Lipari MT; Billeci K; Fan B; Moran P
    FEBS Lett; 2005 Mar; 579(9):1945-50. PubMed ID: 15792801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor.
    Hashimoto T; Kato M; Shimomura T; Kitamura N
    FEBS J; 2010 Dec; 277(23):4888-900. PubMed ID: 20977675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.
    Kataoka H; Hamasuna R; Itoh H; Kitamura N; Koono M
    Cancer Res; 2000 Nov; 60(21):6148-59. PubMed ID: 11085539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases.
    Mukai S; Fukushima T; Naka D; Tanaka H; Osada Y; Kataoka H
    FEBS J; 2008 Mar; 275(5):1003-17. PubMed ID: 18221492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocyte growth factor activator inhibitor type 1 inhibits protease activity and proteolytic activation of human airway trypsin-like protease.
    Kato M; Hashimoto T; Shimomura T; Kataoka H; Ohi H; Kitamura N
    J Biochem; 2012 Feb; 151(2):179-87. PubMed ID: 22023801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pericellular activation of hepatocyte growth factor/scatter factor (HGF/SF) in colorectal carcinomas: roles of HGF activator (HGFA) and HGFA inhibitor type 1 (HAI-1).
    Kataoka H; Itoh H; Hamasuna R; Meng JY; Koono M
    Hum Cell; 2001 Mar; 14(1):83-93. PubMed ID: 11436357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
    Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
    J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defect of pro-hepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis.
    Marchand-Adam S; Fabre A; Mailleux AA; Marchal J; Quesnel C; Kataoka H; Aubier M; Dehoux M; Soler P; Crestani B
    Am J Respir Crit Care Med; 2006 Jul; 174(1):58-66. PubMed ID: 16574935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in plasma levels of hepatocyte growth factor and its associated factors during pregnancy.
    Watanabe T; Sakata Y; Matsubara S; Yamagishi T; Nagaike K; Kuwata T; Suzuki M
    J Obstet Gynaecol Res; 2006 Feb; 32(1):10-4. PubMed ID: 16445520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
    Parr C; Jiang WG
    Int J Cancer; 2006 Sep; 119(5):1176-83. PubMed ID: 16557597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte growth factor activator (HGFA): a serine protease that links tissue injury to activation of hepatocyte growth factor.
    Miyazawa K
    FEBS J; 2010 May; 277(10):2208-14. PubMed ID: 20402766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The hepatocyte growth factor regulatory factors in human breast cancer.
    Parr C; Watkins G; Mansel RE; Jiang WG
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):202-11. PubMed ID: 14734471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocyte growth factor activator inhibitor type 2 lacking the first Kunitz-type serine proteinase inhibitor domain is a predominant product in mouse but not in human.
    Itoh H; Kataoka H; Hamasuna R; Kitamura N; Koono M
    Biochem Biophys Res Commun; 1999 Feb; 255(3):740-8. PubMed ID: 10049781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expressions of molecules associated with hepatocyte growth factor activation after hepatectomy in liver cirrhosis.
    Kaido T; Oe H; Yoshikawa A; Okajima A; Imamura M
    Hepatogastroenterology; 2004; 51(56):547-51. PubMed ID: 15086199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
    Franco FM; Jones DE; Harris PK; Han Z; Wildman SA; Jarvis CM; Janetka JW
    Bioorg Med Chem; 2015 May; 23(10):2328-43. PubMed ID: 25882520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist.
    Kirchhofer D; Lipari MT; Santell L; Billeci KL; Maun HR; Sandoval WN; Moran P; Ridgway J; Eigenbrot C; Lazarus RA
    Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5306-11. PubMed ID: 17372204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.